TUC 150 Pill - yellow oval, 18mm
Generic Name: tucatinib
Pill with imprint TUC 150 is Yellow, Oval and has been identified as Tukysa 150 mg. It is supplied by Seattle Genetics, Inc.
Tukysa is used in the treatment of Breast Cancer; Colorectal Cancer and belongs to the drug class HER2 inhibitors. Tukysa 150 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for TUC 150
Tukysa
- Generic Name
- tucatinib
- Imprint
- TUC 150
- Strength
- 150 mg
- Color
- Yellow
- Size
- 18.00 mm
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- HER2 inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Seattle Genetics, Inc.
- National Drug Code (NDC)
- 51144-0002
See also:
Trodelvy
Trodelvy (sacituzumab govitecan) is a targeted therapy used to treat breast cancer (triple-negative ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Verzenio
Verzenio is used to treat early and advanced-stage hormone receptor-positive, HER2-negative breast ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Kisqali
Kisqali (ribociclib) is used to treat a certain type of advanced metastatic breast cancer. Includes ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Arimidex
Arimidex is used to treat breast cancer in postmenopausal women. Learn about side effects ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Femara
Femara lowers estrogen levels and is used to treat breast cancer in postmenopausal women. Learn ...
More about Tukysa (tucatinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: HER2 inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.